LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced its participation in the Artificial Intelligence & Health Markets 2026 conference, scheduled for August 13 and 14, 2026, at Universidad Santa Maria in Caracas, Venezuela. The event, organized through its Venezuelan subsidiary LATAMEDAI VE, aims to bring together students, faculty, and professionals from systems engineering and healthcare disciplines, including pharmacy, dentistry, and laboratory sciences, to explore practical applications of AI and automation in medical and technical environments.
The company will be represented by Dr. Kevin Rodan Levy, Chief Executive Officer, and Carlos Pena, Chief Financial Officer. Their presentation will address the evolving role of artificial intelligence in healthcare, systems engineering, digital infrastructure, and professional decision-making. LataMed AI intends to discuss how AI-supported tools can assist healthcare professionals with medical-data evaluation, clinical workflows, and operational decision-making, as well as how automation can enhance the organization, reliability, and efficiency of technology systems in healthcare and other complex settings.
A key focus of the presentation will be the importance of maintaining qualified professional oversight when implementing AI. LataMed AI emphasizes that its technologies are designed to enhance human capabilities and support informed decision-making, not replace the independent judgment of healthcare professionals, engineers, laboratory personnel, or other qualified individuals. The conference will also cover topics such as integrating AI and automation into existing systems, responsible data use, privacy and information security, operational risk management, and practical considerations in developing and deploying technology in healthcare settings.
LataMed AI will also discuss the continued development of its healthcare technology ecosystem, including CardioAI, PulmoAI, and NeuroAI platforms, which are being developed to assist healthcare professionals in evaluating and managing cardiovascular, pulmonary, and neurological health information. These platforms remain subject to continued development, testing, regulatory requirements, and commercial implementation.
Dr. Kevin Rodan Levy stated, "Artificial Intelligence & Health Markets 2026 provides an important opportunity to engage directly with students, educators, and future professionals who will help shape the responsible use of artificial intelligence in healthcare and systems engineering. Our objective is to share practical perspectives on how intelligent technologies can support professional decision-making, improve digital workflows, and contribute to the continued development of healthcare infrastructure in Latin America."
The company believes that engagement with universities and educational institutions can increase awareness of emerging healthcare technologies, encourage responsible discussion about AI, and strengthen relationships with future professionals in healthcare, engineering, laboratory, and technology fields. This participation aligns with LataMed AI's broader strategy of supporting education, professional collaboration, and the responsible adoption of digital healthcare infrastructure throughout the region. The company intends to continue evaluating opportunities to participate in academic, healthcare, and technology forums that align with its business and educational objectives.
Participation in the conference does not constitute an endorsement of LataMed AI or its technologies by Universidad Santa Maria. The event does not guarantee future research collaborations, employment arrangements, commercial relationships, technology adoption, regulatory authorization, revenue, or other financial benefits. For additional information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
